Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.

Duggan SP, Garry C, Behan FM, Phipps S, Kudo H, Kirca M, Zaheer A, McGarrigle S, Reynolds JV, Goldin R, Kalloger SE, Schaeffer DF, Long A, Strid J, Kelleher D.

Cell Mol Gastroenterol Hepatol. 2018 Jan 31;5(4):569-590. doi: 10.1016/j.jcmgh.2018.01.012. eCollection 2018.

2.

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.

Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJM, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ.

Cold Spring Harb Mol Case Stud. 2018 Feb 1;4(1). pii: a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.

3.

Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.

Tessier-Cloutier B, Kalloger SE, Al-Kandari M, Milne K, Gao D, Nelson BH, Renouf DJ, Sheffield BS, Schaeffer DF.

BMC Cancer. 2017 Sep 5;17(1):618. doi: 10.1186/s12885-017-3634-5.

4.

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.

Kalloger SE, Riazy M, Tessier-Cloutier B, Karasinska JM, Gao D, Peixoto RD, Samimi S, Chow C, Wong HL, Mackey JR, Renouf DJ, Schaeffer DF.

J Pathol Clin Res. 2017 Jul 19;3(3):179-190. doi: 10.1002/cjp2.75. eCollection 2017 Jul.

5.

Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.

Sheffield BS, Fulton R, Kalloger SE, Milne K, Geller G, Jones M, Jacquemont C, Zachara S, Zhao E, Pleasance E, Laskin J, Jones SJ, Marra MA, Yip S, Nelson BH, Gown AM, Ho C, Ionescu DN.

J Histochem Cytochem. 2016 Oct;64(10):587-600. doi: 10.1369/0022155416665338. Epub 2016 Sep 2.

6.

Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction.

Talhouk A, Kommoss S, Mackenzie R, Cheung M, Leung S, Chiu DS, Kalloger SE, Huntsman DG, Chen S, Intermaggio M, Gronwald J, Chan FC, Ramus SJ, Steidl C, Scott DW, Anglesio MS.

PLoS One. 2016 Apr 20;11(4):e0153844. doi: 10.1371/journal.pone.0153844. eCollection 2016.

7.

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.

Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, Nostro C, Wang R, Muthuswamy LB, Crawford HC, Arrowsmith C, Kalloger SE, Renouf DJ, Connor AA, Cleary S, Schaeffer DF, Roehrl M, Tsao MS, Gallinger S, Keller G, Muthuswamy SK.

Nat Med. 2015 Nov;21(11):1364-71. doi: 10.1038/nm.3973. Epub 2015 Oct 26.

8.

Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups.

Leo JM, Kalloger SE, Peixoto RD, Gale NS, Webber DL, Owen DA, Renouf D, Schaeffer DF.

J Clin Pathol. 2016 May;69(5):431-9. doi: 10.1136/jclinpath-2015-203337. Epub 2015 Oct 23.

PMID:
26500334
9.

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.

Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU.

Oncotarget. 2015 Nov 17;6(36):39088-97. doi: 10.18632/oncotarget.5142. Review.

10.

Gastrointestinal Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy Specimens: Adequate Diagnostic Yield and Accuracy Can Be Achieved without On-Site Evaluation.

O'Connor K, Cheriyan DG, Li-Chang HH, Kalloger SE, Garrett J, Byrne MF, Weiss AA, Donnellan F, Schaeffer DF.

Acta Cytol. 2015;59(4):305-10. doi: 10.1159/000439398. Epub 2015 Sep 5.

PMID:
26339900
11.

Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.

Riazy M, Kalloger SE, Sheffield BS, Peixoto RD, Li-Chang HH, Scudamore CH, Renouf DJ, Schaeffer DF.

Mod Pathol. 2015 Oct;28(10):1383-9. doi: 10.1038/modpathol.2015.89. Epub 2015 Jul 31.

12.

Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.

O'Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, Driman DK, Kirsch R, Serra S, Scudamore CH, Renouf DJ, Schaeffer DF.

Am J Surg Pathol. 2015 Apr;39(4):472-8. doi: 10.1097/PAS.0000000000000333.

PMID:
25634751
13.

HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.

Sheffield BS, Garratt J, Kalloger SE, Li-Chang HH, Torlakovic EE, Gilks CB, Schaeffer DF.

Arch Pathol Lab Med. 2014 Nov;138(11):1495-502. doi: 10.5858/arpa.2013-0604-OA.

PMID:
25357111
14.

Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas.

Alsolami S, El-Bahrawy M, Kalloger SE, AlDaoud N, Pathak TB, Chung CT, Mulligan AM, Tomlinson IP, Pollard PJ, Gilks CB, McCluggage WG, Clarke BA.

Int J Gynecol Pathol. 2014 Nov;33(6):560-7. doi: 10.1097/PGP.0000000000000091. Erratum in: Int J Gynecol Pathol. 2015 Mar;34(2):213. Cheung, Catherine T [corrected to Chung, Catherine T].

PMID:
25272294
15.

Determinants of quality of life in ovarian cancer survivors: a pilot study.

Teng FF, Kalloger SE, Brotto L, McAlpine JN.

J Obstet Gynaecol Can. 2014 Aug;36(8):708-715. doi: 10.1016/S1701-2163(15)30513-2.

PMID:
25222166
16.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

Le Page C, Köbel M, de Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piché A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM.

Biopreserv Biobank. 2013 Apr;11(2):83-93. doi: 10.1089/bio.2012.0044. Erratum in: Biopreserv Biobank. 2013 Aug;11(4):257. Roehrl, Michael H A [added].

PMID:
24845429
17.

ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts.

Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF.

Hum Pathol. 2014 Jun;45(6):1258-68. doi: 10.1016/j.humpath.2014.02.006. Epub 2014 Feb 20.

PMID:
24767857
18.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

19.

Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.

Townsend KN, Spowart JE, Huwait H, Eshragh S, West NR, Elrick MA, Kalloger SE, Anglesio M, Watson PH, Huntsman DG, Lum JJ.

PLoS One. 2013 Dec 23;8(12):e82406. doi: 10.1371/journal.pone.0082406. eCollection 2013.

20.

Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 27;8(9). doi: 10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a. eCollection 2013.

21.

Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.

Ali RH, Kalloger SE, Santos JL, Swenerton KD, Gilks CB.

Int J Gynecol Pathol. 2013 Nov;32(6):529-35. doi: 10.1097/PGP.0b013e31827630eb.

PMID:
24071867
22.

Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.

Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J.

Histopathology. 2013 Nov;63(5):704-12. doi: 10.1111/his.12219. Epub 2013 Sep 2.

PMID:
24033430
23.

Type-specific cell line models for type-specific ovarian cancer research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 4;8(9):e72162. doi: 10.1371/journal.pone.0072162. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/856f0890-9d85-4719-8e54-c27530ac94f4. PLoS One. 2013;8(9). doi:10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a.

24.

Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL; Ovarian Tumor Tissue Analysis consortium.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86. doi: 10.1158/1055-9965.EPI-13-0391. Epub 2013 Jul 23.

25.

Reproducibility of histological cell type in high-grade endometrial carcinoma.

Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, Ewanowich CA, Kalloger SE, Köbel M.

Mod Pathol. 2013 Dec;26(12):1594-604. doi: 10.1038/modpathol.2013.102. Epub 2013 Jun 28.

26.

Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.

Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA, Lange CA.

Cell Cycle. 2013 May 1;12(9):1433-49. doi: 10.4161/cc.24550. Epub 2013 Apr 10.

27.

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.

Altman AD, Nelson GS, Ghatage P, McIntyre JB, Capper D, Chu P, Nation JG, Karnezis AN, Han G, Kalloger SE, Köbel M.

Mod Pathol. 2013 Sep;26(9):1255-63. doi: 10.1038/modpathol.2013.55. Epub 2013 Apr 5.

28.

BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.

Beirne JP, Quinn JE, Maxwell P, Kalloger SE, McAlpine J, Gilks CB, Harley IJ, McCluggage WG.

Int J Gynecol Cancer. 2013 Jan;23(1):113-8. doi: 10.1097/IGC.0b013e3182798188.

PMID:
23221734
29.

Quantification of ER/PR expression in ovarian low-grade serous carcinoma.

Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Köbel M.

Gynecol Oncol. 2013 Feb;128(2):371-6. doi: 10.1016/j.ygyno.2012.10.013. Epub 2012 Oct 24.

PMID:
23103384
30.

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff BJ, Kalloger SE, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia JJ, Schoolmeester JK, Bakkum-Gamez J, Tinker AV, Bowtell DD, Huntsman DG, Gilks CB, McAlpine JN.

J Pathol. 2013 Jan;229(1):111-20. doi: 10.1002/path.4088.

PMID:
22899400
31.

Architectural patterns of ovarian/pelvic high-grade serous carcinoma.

Bromley AB, Altman AD, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Han G, Köbel M.

Int J Gynecol Pathol. 2012 Sep;31(5):397-404. doi: 10.1097/PGP.0b013e31824c2372.

PMID:
22833078
32.

Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.

Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, Gilks CB, McAlpine JN.

Obstet Gynecol. 2012 Aug;120(2 Pt 1):235-40. doi: 10.1097/AOG.0b013e31825f3576.

PMID:
22776961
33.

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes.

Milne K, Alexander C, Webb JR, Sun W, Dillon K, Kalloger SE, Gilks CB, Clarke B, Köbel M, Nelson BH.

J Transl Med. 2012 Feb 27;10:33. doi: 10.1186/1479-5876-10-33.

34.

Use of mismatch repair immunohistochemistry and microsatellite instability testing: exploring Canadian practices.

Kalloger SE, Allo G, Mulligan AM, Pollett A, Aronson M, Gallinger S, Torlakovic EE, Clarke BA.

Am J Surg Pathol. 2012 Apr;36(4):560-9. doi: 10.1097/PAS.0b013e31823f3b28.

PMID:
22301492
35.

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.

McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.

Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.

36.

The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma.

Cipollone JA, Graves ML, Köbel M, Kalloger SE, Poon T, Gilks CB, McNagny KM, Roskelley CD.

Clin Exp Metastasis. 2012 Mar;29(3):239-52. doi: 10.1007/s10585-011-9446-0. Epub 2012 Jan 20.

PMID:
22262060
37.

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG.

N Engl J Med. 2012 Jan 19;366(3):234-42. doi: 10.1056/NEJMoa1102903. Epub 2011 Dec 21.

38.

Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries.

Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, Holter S, Kwon J, Kalloger SE, Gilks CB, Gallinger S, Pollett A, Clarke BA.

Cancer. 2012 Feb 1;118(3):681-8. doi: 10.1002/cncr.26323. Epub 2011 Jun 30.

39.

Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites.

Köbel M, Turbin D, Kalloger SE, Gao D, Huntsman DG, Gilks CB.

Int J Gynecol Pathol. 2011 Jul;30(4):366-71. doi: 10.1097/PGP.0b013e31820d20ba.

PMID:
21623201
40.

Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.

Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG.

J Pathol. 2011 Jul;224(3):328-33. doi: 10.1002/path.2911. Epub 2011 May 18.

PMID:
21590771
41.

Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation.

Boylan KL, Misemer B, De Rycke MS, Andersen JD, Harrington KM, Kalloger SE, Gilks CB, Pambuccian SE, Skubitz AP.

Int J Mol Sci. 2011 Feb 22;12(2):1334-58. doi: 10.3390/ijms12021334.

42.

In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.

Elschenbroich S, Ignatchenko V, Clarke B, Kalloger SE, Boutros PC, Gramolini AO, Shaw P, Jurisica I, Kislinger T.

J Proteome Res. 2011 May 6;10(5):2286-99. doi: 10.1021/pr1011087. Epub 2011 Apr 14.

PMID:
21491939
43.

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.

McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM; Australian Ovarian Cancer Study Group, Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, Gilks CB, Huntsman DG.

J Pathol. 2011 Apr;223(5):567-73. doi: 10.1002/path.2848. Epub 2011 Mar 7.

PMID:
21381030
44.

FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary.

Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, Huntsman DG, Young RH, Gilks CB.

Am J Surg Pathol. 2011 Apr;35(4):484-94. doi: 10.1097/PAS.0b013e31820a406c.

PMID:
21378549
45.

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.

Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD.

Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22.

46.

Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection.

McAlpine JN, El Hallani S, Lam SF, Kalloger SE, Luk M, Huntsman DG, MacAulay C, Gilks CB, Miller DM, Lane PM.

Gynecol Oncol. 2011 Mar;120(3):385-92. doi: 10.1016/j.ygyno.2010.12.333. Epub 2011 Jan 14.

PMID:
21237503
47.

Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review.

Krizova A, Clarke BA, Bernardini MQ, James S, Kalloger SE, Boerner SL, Mulligan AM.

Am J Surg Pathol. 2011 Jan;35(1):115-26. doi: 10.1097/PAS.0b013e31820273dc.

PMID:
21164295
48.

Calculator for ovarian carcinoma subtype prediction.

Kalloger SE, Köbel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB.

Mod Pathol. 2011 Apr;24(4):512-21. doi: 10.1038/modpathol.2010.215. Epub 2010 Dec 3.

49.

Quantification of lung surface area using computed tomography.

Yuan R, Nagao T, Paré PD, Hogg JC, Sin DD, Elliott MW, Loy L, Xing L, Kalloger SE, English JC, Mayo JR, Coxson HO.

Respir Res. 2010 Oct 31;11:153. doi: 10.1186/1465-9921-11-153.

50.

Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker.

Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP.

Am J Clin Pathol. 2010 Nov;134(5):835-45. doi: 10.1309/AJCPGXK0FR4MHIHB.

Supplemental Content

Loading ...
Support Center